<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40388727</article-id><article-id pub-id-type="pmc">PMC12091621</article-id>
<article-id pub-id-type="publisher-id">MD-D-24-11759</article-id><article-id pub-id-type="art-access-id">00008</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000042311</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="heading"><subject>5100</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>Causal relationship between metabolic dysfunction-associated fatty liver disease and endotoxin biomarkers: A Mendelian randomization study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-3942-2237</contrib-id><name><surname>Kong</surname><given-names>Jingwen</given-names></name><degrees>MS</degrees><email>kongjingwen@bjzyydx.wecom.work</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Xixi</given-names></name><degrees>MS</degrees><email>3285456196@qq.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wei</surname><given-names>Chao</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label> Jining Medical University, Jining, China</aff><aff id="aff2"><label>b</label> Beijing University of Chinese Medicine, Beijing, China.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Chao Wei, Jining Medical University, Jining 272008, China (e-mail: <email xlink:href="qw26010539@163.com">qw26010539@163.com</email>).</corresp></author-notes><pub-date pub-type="collection"><day>16</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2025</year></pub-date><volume>104</volume><issue>20</issue><elocation-id>e42311</elocation-id><history><date date-type="received"><day>29</day><month>9</month><year>2024</year></date><date date-type="received"><day>29</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="medi-104-e42311.pdf"/><abstract><p>Although the relationship among lipopolysaccharides (LPS), LPS-binding proteins, and metabolic dysfunction-associated fatty liver disease (MAFLD) is widely studied, no conclusive evidence is available. In this study, we used mendelian randomization (MR) to study the causal relationship of LPS, LPS-binding proteins, and MAFLD. Using bidirectional two-sample MR method, we evaluated data from the genome wide association study; for this analysis, nonalcoholic fatty liver disease (NAFLD), liver fat percentage, and other metabolic syndromes were employed as outcomes. Furthermore, MR analysis mainly involved the inverse variance weighted method. Heterogeneity and pleiotropy tests were also conducted. LPS was found to have a causal relationship with NAFLD, obesity, high density lipoprotein cholesterol, and TG levels. Furthermore, TG levels and LBP had significant causal relationships. This study mainly concluded that LPS is a risk factor for NAFLD, obesity, high density lipoprotein cholesterol, and TG, corroborating it&#x02019;s the LPS role in MAFLD pathogenesis. Hence, optimizing the gut microbiota using proper diet, probiotics, or fecal microbiota transplantation may help to reduce inflammation and (IR), thereby improving lipid and glucose metabolism disorders. Although a causal relationship between TG and LBP was observed, further studies are required to determine a specific mechanism.</p></abstract><kwd-group><kwd>lipopolysaccharides</kwd><kwd>LPS-binding proteins</kwd><kwd>Mendelian randomization</kwd><kwd>metabolic dysfunction-associated fatty liver disease</kwd></kwd-group><funding-group><award-group id="ID0EM5AE133448"><funding-source>Shandong Provincial Key Laboratory of Traditional Chinese Medicine</funding-source><award-id>[No. (2022)4].</award-id><principal-award-recipient>Jingwen Kong</principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Nonalcoholic fatty liver disease (NAFLD) is characterized by an excessive deposition of fat in liver cells; this fat accumulation is not due to alcohol consumption or other clear causes. The incidence rate of NAFLD is approximately 38% and is showing increasing trend in recent years.<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup> In 2022, 134 medical groups recognized the need to rename NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD) because the latter term emphasizes the importance of metabolic disorders in the occurrence and development of fatty liver, and hence can better guide clinical targeted management.<sup>[<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>]</sup> In case of liver steatosis, MAFLD can be diagnosed if obesity or type 2 diabetes mellitus (T2DM) is present; however, if the body weight is within normal clinical range, &#x0003e;2 risk factors (increased waist circumference, hypertension, hypertriglyceridemia, low high density lipoprotein cholesterol (HDL-c) level, abnormal fasting blood glucose (FBG), insulin resistance and chronic inflammatory) of metabolic disorder should be present.<sup>[<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>]</sup> Due to adverse changes in lifestyle, there is a considerable increase in the occurrence frequency of various metabolic syndromes, such as obesity, T2DM, and atherogenic dyslipidemia (AD). Such metabolic disorders not only pose risk for MAFLD, but also may lead to serious liver complications and cardiovascular diseases, increasing mortality risk for such patients.<sup>[<xref rid="R7" ref-type="bibr">7</xref>&#x02013;<xref rid="R9" ref-type="bibr">9</xref>]</sup></p><p>The importance of increased lipopolysaccharide (LPS) levels in the liver during NAFLD is extensively studied. LPS, which is a component of Gram-negative bacterial outer membrane and a potent endotoxin, can be accumulated in the liver by forming LPS-binding protein (LBP) complexes, in turn initiating a series of inflammatory reactions in the liver.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> LPS penetrates the bloodstream through the intestinal mucosa, instigating inflammatory reactions by engaging the Toll-like receptor 4 (TLR4). Upon arriving at the liver, LPS stimulates TLR4-mediated inflammation within hepatocytes, which plays a role in the progression of NAFLD among overweight and obese individuals.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> Meanwhile, LPS is an important factor in regulating lipid metabolism and can increase TG synthesis in the liver.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> LPS can also lead to oxidative stress and mitochondrial damage, playing an important role in the process of liver inflammation.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> Experimentally reduced liver LBP levels, whether in standard conditions or non-obesogenic factors, intensify liver inflammation, fibrosis, and oxidative stress in nonalcoholic steatohepatitis (NASH) in mouse models.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> Elevated serum LPS and LBP levels in rat model of NAFLD associated with obesity.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> Further, high serum LPS and LBP levels predicted high level of obesity in children and indicated risk for the development of metabolic syndrome in adolescents.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> However, contrast results were also reported; individuals with obesity showed increased LBP levels but a negative correlation with T2DM, NAFLD, and nonalcoholic steatosis (NASH). According to these results, LBP may serve as a protective factor, mitigating the adverse metabolic consequences associated with obesity.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> Contrasting results have also been observed in terms of circulating LPS levels in patients with T2DM. Since these data were obtained from studies with different designs, such as cross-sectional studies, population surveys, and cohorts, confounding factors and reverse causal effects are inevitable.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup></p><p>Mendelian randomization (MR) is a study of mendelian inheritance based on the random allocation of alleles from parents to offspring; this process is equivalent to that of random allocation of participants in randomized controlled trials. MR is advantageous because it is not affected by traditional confounding factors and satisfies temporal rationality. The basic idea is to use genetic variations strongly correlated with exposure factors as instrumental variables to infer causal effects between exposure and outcome.<sup>[<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref>]</sup> This study aimed to employ MR to understand the bidirectional causal relationship among various metabolic disorders related to MAFLD and LPS, and LBP. We also explored the mechanism of interaction between LPS, LBP, and MAFLD.</p></sec><sec sec-type="methods"><title>2. Materials and methods</title><sec><title>2.1. Study design</title><p>The genome wide association study (GWAS) database was used to perform a two sample bidirectional MR analysis. We followed the following 3 MR hypotheses: single nucleotide polymorphism (SNP) is strongly correlated with exposure, SNP is independent of confounding factors that affect exposure and outcomes, and SNP can only affect outcomes through exposure rather than other pathways. The three major hypotheses and variables of this study are shown in Figure <xref rid="F1" ref-type="fig">1</xref>. After satisfying the three major hypotheses of Mendelian randomization, we conducted correlation setting, independence setting, and statistical strength setting, calculated P-values and F-values, and then conducted heterogeneity testing and sensitivity analysis to obtain funnel plots and forest plots.</p><fig position="float" id="F1"><label>Figure 1.</label><caption><p>Graphical Abstract: the 3 assumptions of Mendelian randomization analysis.</p></caption><graphic xlink:href="medi-104-e42311-g001" position="float"/></fig></sec><sec><title>2.2. Data sources</title><p>NAFLD, liver fat percentage, and factors related to metabolic disorders were considered as outcomes. The large-scale GWAS meta-analysis (included the UK Biobank, eMERGE, FinnGen cohorts, and Estonian Biobank) was the source for NAFLD data. The diagnostic criteria were based on EHR codes except conditions, such as alcoholic liver disease, hepatitis, and inbound errors of metabolism.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> Considering the important association between visceral fat and NAFLD, liver fat percentage was also considered; the data were obtained from the UK Biobank abdominal magnetic resonance imaging. Overweight data were obtained fom the European population of 51 studies conducted by the Genetic Investigation of ANthropometric Traits (GIANT).<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> Obesity data were from European ethnicities, including 4793 patients with obesity and 209884 with no obesity. UKB, GERA, and DIAGRAM databases were the sources for T2DM data, with the majority being European and a small portion from Pakistan.<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> Waist circumference and hypertension data were from the UKBiobank database (European descent). Data on HDL-c were from a longitudinal study of British households, and blood samples were collected for testing and analysis.<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> Triglyceride (TG) level data were from the UK Biobank.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> FBG data from 58070 non-diabetes European individuals recruited from 29 MAGIC studies.<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup> Insulin resistance (IR) data were also from individuals with no diabetes in MAGIC study.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup> Serum LPS activity data were from Finnish Twin Cohort (Adult Finnish twins), FinnDiane (type 1 diabetes and unclassified diabetes), and FINRISK (Finnish population); the serum LPS activity was measured by using either spectrometry-based method or via the methods of limulus amebocyte lysate (LAL).<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> LBP is a cohort from a Finnish study in which participants were recruited for the general surgery in the UK region. Based on proteomic analysis, the fasting plasma EDTA levels were measured.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> All databases utilized are publicly available and were approved by the ethics committees of original studies. Furthermore, all participants in those studies provided consent for participation. Hence, additional ethics approval or consent was not required. Table <xref rid="T1" ref-type="table">1</xref> lists features all databases employed.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>The basic characteristics of GWAS data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Trait</th><th align="center" rowspan="1" colspan="1">GWAS ID</th><th align="center" rowspan="1" colspan="1">Consortium</th><th align="center" rowspan="1" colspan="1">Population</th><th align="center" rowspan="1" colspan="1">Sample size (case/control)</th><th align="center" rowspan="1" colspan="1">PMID</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">NAFLD</td><td align="center" rowspan="1" colspan="1">ebi-a-GCST90091033</td><td align="center" rowspan="1" colspan="1">eMERGE&#x02005;+&#x02005;UK Biobank&#x02005;+&#x02005;FinnGen&#x02005;+&#x02005;Estonian Biobank</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">778,614 (8434/770,180)</td><td align="center" rowspan="1" colspan="1">34841290</td></tr><tr><td align="left" rowspan="1" colspan="1">Percent liver fat</td><td align="center" rowspan="1" colspan="1">ebi-a-GCST90016673</td><td align="center" rowspan="1" colspan="1">UK Biobank</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">32,858</td><td align="center" rowspan="1" colspan="1">34128465</td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight</td><td align="center" rowspan="1" colspan="1">ieu-a-93</td><td align="center" rowspan="1" colspan="1">Genetic Investigation of ANthropometric Traits (GIANT)</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">158855</td><td align="center" rowspan="1" colspan="1">23563607</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity</td><td align="center" rowspan="1" colspan="1">finn-b-E4_OBESITYNAS</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">214677 (4793/209,884)</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">T2DM</td><td align="center" rowspan="1" colspan="1">ebi-a-GCST006867</td><td align="center" rowspan="1" colspan="1">DIAbetes Genetics Replication and Meta-analysis (DIAGRAM)&#x02005;+&#x02005;Genetic Epidemiology Research on Adult Health and Aging (GERA)&#x02005;+&#x02005;UKB</td><td align="center" rowspan="1" colspan="1">European&#x02005;+&#x02005;Pakistan</td><td align="center" rowspan="1" colspan="1">655,666 (61,714/1178)</td><td align="center" rowspan="1" colspan="1">30054458</td></tr><tr><td align="left" rowspan="1" colspan="1">WC</td><td align="center" rowspan="1" colspan="1">ukb-b-9405</td><td align="center" rowspan="1" colspan="1">UKBiobank</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">462,166</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">ukb-b-14057</td><td align="center" rowspan="1" colspan="1">UKBiobank</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">462,933 (119,731/343,202)</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-C</td><td align="center" rowspan="1" colspan="1">ebi-a-GCST005058</td><td align="center" rowspan="1" colspan="1">The United Kingdom Household Longitudinal Study</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">9796</td><td align="center" rowspan="1" colspan="1">28887542</td></tr><tr><td align="left" rowspan="1" colspan="1">TG levels</td><td align="center" rowspan="1" colspan="1">ebi-a-GCST90025957</td><td align="center" rowspan="1" colspan="1">UKBiobank</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">437,532</td><td align="center" rowspan="1" colspan="1">34226706</td></tr><tr><td align="left" rowspan="1" colspan="1">FBG</td><td align="center" rowspan="1" colspan="1">ebi-a-GCST005186</td><td align="center" rowspan="1" colspan="1">Glucose and Insulin-related traits Consortium (MAGIC)</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">58,074</td><td align="center" rowspan="1" colspan="1">22581228</td></tr><tr><td align="left" rowspan="1" colspan="1">IR</td><td align="center" rowspan="1" colspan="1">ebi-a-GCST005179</td><td align="center" rowspan="1" colspan="1">Glucose and Insulin-related traits Consortium (MAGIC)</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">37,037</td><td align="center" rowspan="1" colspan="1">20081858</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS</td><td align="center" rowspan="1" colspan="1">ebi-a-GCST90032674</td><td align="center" rowspan="1" colspan="1">FinnDiane, FINRISK and Finnish Twin Cohort</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">11,296</td><td align="center" rowspan="1" colspan="1">34668383</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP</td><td align="center" rowspan="1" colspan="1">ebi-a-GCST90019429</td><td align="center" rowspan="1" colspan="1">The Fenland study</td><td align="center" rowspan="1" colspan="1">European</td><td align="center" rowspan="1" colspan="1">10,708</td><td align="center" rowspan="1" colspan="1">33328453</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>FBG = fasting blood glucose, IR = insulin resistance, LBP = lipopolysaccharide-binding protein, LPS = lipopolysaccharide, NAFLD = nonalcoholic fatty liver disease; T2DM = type 2 diabetes, TG = triglyceride levels, WC = waist circumference.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>2.3. Selection of inverse variances</title><p>Screening of SNPs (with <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;8</sup> from the GWAS) strongly correlated with exposure factors (significance adjusted to <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;6</sup> when the number of SNPs was small).<sup>[<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref>]</sup> To remove the linkage imbalance among SNPs, satisfying <italic toggle="yes">r</italic><sup>2</sup>&#x02005;=&#x02005;0.001 and kb&#x02005;=&#x02005;10,000 was essential. After deleting palindromic SNPs, we used PhenoScanner website to exclude SNPs associated with confounding factors. We eventually calculated the F value (equation 1) and <italic toggle="yes">R</italic><sup>2</sup>value (equation 2) for each SNP, excluding weak variables with F&#x02005;&#x0003c;&#x02005;10.<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup></p><disp-formula><mml:math id="M1" overflow="scroll"><mml:mstyle displaystyle="true"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>k</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>k</mml:mi></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:math>
<label>(1)</label></disp-formula><disp-formula><mml:math id="M2" overflow="scroll"><mml:mstyle displaystyle="true"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">F</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:math>
<label>(2)</label></disp-formula></sec><sec><title>2.4. Statistical analysis</title><p>MR analysis involved inverse variance weighted (IVW) supplemented by weight median (WM), MR Egger, simple mode, and weighted mode. The MRPRESSO package (V1.0) was used; it detects outlier SNPs and then eliminates them for re-analysis and result comparison. We selected SNPs with <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;8</sup> or <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;6</sup>, When a threshold of <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;6</sup> was applied to remove linkage disequilibrium (<italic toggle="yes">r</italic><sup>2</sup>&#x02005;=&#x02005;0.001, kb&#x02005;=&#x02005;10,000). With F-values greater than 10, and then removed the palindrome sequence. Sensitivity analysis of MR results was performed using Cochran&#x02019;s Q-test results (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.05 indicated gene heterogeneity). MR-Egger intercept analysis was used to test gene pleiotropy (<italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;.05 indicated horizontal pleiotropy) and leave-one-out method was used to test result stability by removing SNPs. All statistical analyses were conducted using the TwoSampleMR package (V 0.6.1) in R version 4.3.3.</p></sec></sec><sec sec-type="results"><title>3. Results</title><sec sec-type="results"><title>3.1. Inverse variance screening results</title><p>We first used a significance threshold of <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;8</sup> or <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;6</sup> and obtained six SNPs related to LPS and LBP each. 18 and 19 SNPs related to LPS and LBP, respectively, were obtained. On the PhenoScanner website, no SNP related to confounding factors was obtained. For observed SNPs, the F values were&#x02005;&#x0003e;&#x02005;10, indicating strong correlation. Subsequently, we extracted the information of these SNPs in MAFLD, removed the palindrome sequence, and removed outlier SNPs using MRPRESSO, and finally obtained inverse variances for the MR analysis. The inverse variance screening process in case of reverse MR is described in Table S1, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O880" ext-link-type="uri">https://links.lww.com/MD/O880</ext-link>.</p></sec><sec><title>3.2. Bilateral MR of LPS and MAFLD</title><p>LPS was found to have a causal relationship with NAFLD (odds ratio [OR]: 1.114, 95% confidence interval [CI]: 1.024&#x02013;1.211, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.012), obesity (OR: 1.148, 95% CI: 1.007&#x02013;1.308, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.039), HDL-c (OR: 0.920, 95% CI: 0.860&#x02013;0.984, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.015), triglyceride levels (OR: 1.015, 95% CI: 1.001&#x02013;1.029, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.037); hence, increasing LPS levels led to an increased incidence of NAFLD and obesity, decreased levels of HDL-c, and increased TG levels (Figure S1, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O881" ext-link-type="uri">https://links.lww.com/MD/O881</ext-link> the Scatter plot, funnel plot, forest plot, and leave-one-out sensitivity analysis in MR analysis). Heterogeneity was also observed between LPS levels and the occurrence of obesity (Cochran&#x02019;s Q&#x02005;=&#x02005;23.365, Q <italic toggle="yes">P</italic> value&#x02005;=&#x02005;.038) Notably, no significant heterogeneity was observed between LPS and other results. Moreover, in the MR-PRESSO global test, no horizontal pleiotropy was observed in the overall instrumental variables, and the outlier corrected test showed no outlier SNPs. Other tests, such as the MR Egger intercept test that indicated no pleiotropy and the leave-one-out sensitivity analysis (based on SNP positioning), also demonstrated robustness of conclusions. The reverse MR analysis showed that NAFLD, liver fat percentage, overweight, obesity, HDL-c, FBG, and IR (analysis significance threshold of <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;6</sup>) as well as T2DM, waist circumference, hypertension, and TG levels (analysis significance threshold of <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;8</sup>) were not risk factors for elevated LPS levels. Table <xref rid="T2" ref-type="table">2</xref> shows the results of heterogeneity, pleiotropy, and MR-PRESSO tests, whereas Figures <xref rid="F2" ref-type="fig">2</xref> and <xref rid="F3" ref-type="fig">3</xref> show forest maps.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Heterogeneity test, Pleiotropy test and MR-PRESSO test.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Exposure</th><th align="center" rowspan="1" colspan="1">Cochran&#x02019;s Q <italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">egger_intercept</th><th align="center" rowspan="1" colspan="1">MR-PRESSO global test <italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LPS-NAFLD</td><td align="center" rowspan="1" colspan="1">.200</td><td align="center" rowspan="1" colspan="1">0.548</td><td align="center" rowspan="1" colspan="1">.302</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-Percent liver fat</td><td align="center" rowspan="1" colspan="1">.10</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">.168</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-Overweight</td><td align="center" rowspan="1" colspan="1">.175</td><td align="center" rowspan="1" colspan="1">0.636</td><td align="center" rowspan="1" colspan="1">.387</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-Obesity</td><td align="center" rowspan="1" colspan="1">.038</td><td align="center" rowspan="1" colspan="1">0.576</td><td align="center" rowspan="1" colspan="1">.058</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-Type 2 diabetes</td><td align="center" rowspan="1" colspan="1">.707</td><td align="center" rowspan="1" colspan="1">0.464</td><td align="center" rowspan="1" colspan="1">.673</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-Waist circumference</td><td align="center" rowspan="1" colspan="1">.047</td><td align="center" rowspan="1" colspan="1">0.783</td><td align="center" rowspan="1" colspan="1">.078</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-Hypertension</td><td align="center" rowspan="1" colspan="1">.00</td><td align="center" rowspan="1" colspan="1">0.1608361</td><td align="center" rowspan="1" colspan="1">.022</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-HDL-c levels</td><td align="center" rowspan="1" colspan="1">.387</td><td align="center" rowspan="1" colspan="1">0.306</td><td align="center" rowspan="1" colspan="1">.493</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-Triglyceride levels</td><td align="center" rowspan="1" colspan="1">.576</td><td align="center" rowspan="1" colspan="1">0.317</td><td align="center" rowspan="1" colspan="1">.431</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-Fasting blood glucose</td><td align="center" rowspan="1" colspan="1">.9569845</td><td align="center" rowspan="1" colspan="1">0.8969849</td><td align="center" rowspan="1" colspan="1">.987</td></tr><tr><td align="left" rowspan="1" colspan="1">LPS-Insulin resistance</td><td align="center" rowspan="1" colspan="1">.9746196</td><td align="center" rowspan="1" colspan="1">0.2985206</td><td align="center" rowspan="1" colspan="1">.94</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-NAFLD</td><td align="center" rowspan="1" colspan="1">.9087747</td><td align="center" rowspan="1" colspan="1">0.3668788</td><td align="center" rowspan="1" colspan="1">.873</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-Percent liver fat</td><td align="center" rowspan="1" colspan="1">.4626318</td><td align="center" rowspan="1" colspan="1">0.2126812</td><td align="center" rowspan="1" colspan="1">.392</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-Overweight</td><td align="center" rowspan="1" colspan="1">.87988</td><td align="center" rowspan="1" colspan="1">0.5661833</td><td align="center" rowspan="1" colspan="1">.974</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-Obesity</td><td align="center" rowspan="1" colspan="1">.8266659</td><td align="center" rowspan="1" colspan="1">0.3229417</td><td align="center" rowspan="1" colspan="1">.904</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-Type 2 diabetes</td><td align="center" rowspan="1" colspan="1">.08268243</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-Waist circumference</td><td align="center" rowspan="1" colspan="1">1.77E-09</td><td align="center" rowspan="1" colspan="1">0.4748781</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-Hypertension</td><td align="center" rowspan="1" colspan="1">.000830803</td><td align="center" rowspan="1" colspan="1">0.7266216</td><td align="center" rowspan="1" colspan="1">.031</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-HDL-c levels</td><td align="center" rowspan="1" colspan="1">.370</td><td align="center" rowspan="1" colspan="1">0.439</td><td align="center" rowspan="1" colspan="1">.402</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-Triglyceride levels</td><td align="center" rowspan="1" colspan="1">.000641233</td><td align="center" rowspan="1" colspan="1">0.2758084</td><td align="center" rowspan="1" colspan="1">.065</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-Fasting blood glucose</td><td align="center" rowspan="1" colspan="1">.7800669</td><td align="center" rowspan="1" colspan="1">0.900061</td><td align="center" rowspan="1" colspan="1">.817</td></tr><tr><td align="left" rowspan="1" colspan="1">LBP-Insulin resistance</td><td align="center" rowspan="1" colspan="1">.6633514</td><td align="center" rowspan="1" colspan="1">0.5850178</td><td align="center" rowspan="1" colspan="1">.919</td></tr><tr><td align="left" rowspan="1" colspan="1">NAFLD-LPS</td><td align="center" rowspan="1" colspan="1">.529</td><td align="center" rowspan="1" colspan="1">0.278</td><td align="center" rowspan="1" colspan="1">.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Percent liver fat-LPS</td><td align="center" rowspan="1" colspan="1">.559</td><td align="center" rowspan="1" colspan="1">0.347</td><td align="center" rowspan="1" colspan="1">.267</td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight-LPS</td><td align="center" rowspan="1" colspan="1">.556</td><td align="center" rowspan="1" colspan="1">0.201</td><td align="center" rowspan="1" colspan="1">.642</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity-LPS</td><td align="center" rowspan="1" colspan="1">.309</td><td align="center" rowspan="1" colspan="1">0.277</td><td align="center" rowspan="1" colspan="1">.241</td></tr><tr><td align="left" rowspan="1" colspan="1">Type 2 diabetes-LPS</td><td align="center" rowspan="1" colspan="1">.237</td><td align="center" rowspan="1" colspan="1">0.162</td><td align="center" rowspan="1" colspan="1">.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference-LPS</td><td align="center" rowspan="1" colspan="1">.965</td><td align="center" rowspan="1" colspan="1">0.958</td><td align="center" rowspan="1" colspan="1">.848</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension-LPS</td><td align="center" rowspan="1" colspan="1">.088</td><td align="center" rowspan="1" colspan="1">0.058</td><td align="center" rowspan="1" colspan="1">.174</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-c levels-LPS</td><td align="center" rowspan="1" colspan="1">1.505&#x02005;&#x000d7;&#x02005;10-6</td><td align="center" rowspan="1" colspan="1">0.173</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglyceride levels-LPS</td><td align="center" rowspan="1" colspan="1">.009</td><td align="center" rowspan="1" colspan="1">0.329</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting blood glucose-LPS</td><td align="center" rowspan="1" colspan="1">.807</td><td align="center" rowspan="1" colspan="1">0.163</td><td align="center" rowspan="1" colspan="1">.285</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin resistance-LPS</td><td align="center" rowspan="1" colspan="1">.537</td><td align="center" rowspan="1" colspan="1">0.874</td><td align="center" rowspan="1" colspan="1">.234</td></tr><tr><td align="left" rowspan="1" colspan="1">NAFLD-LBP</td><td align="center" rowspan="1" colspan="1">.053</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">.135</td></tr><tr><td align="left" rowspan="1" colspan="1">Percent liver fat-LBP</td><td align="center" rowspan="1" colspan="1">.35</td><td align="center" rowspan="1" colspan="1">0.736</td><td align="center" rowspan="1" colspan="1">.162</td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight-LBP</td><td align="center" rowspan="1" colspan="1">.231</td><td align="center" rowspan="1" colspan="1">0.971</td><td align="center" rowspan="1" colspan="1">.559</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity-LBP</td><td align="center" rowspan="1" colspan="1">.879</td><td align="center" rowspan="1" colspan="1">0.597</td><td align="center" rowspan="1" colspan="1">.911</td></tr><tr><td align="left" rowspan="1" colspan="1">Type 2 diabetes-LBP</td><td align="center" rowspan="1" colspan="1">.463</td><td align="center" rowspan="1" colspan="1">0.098</td><td align="center" rowspan="1" colspan="1">.214</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference-LBP</td><td align="center" rowspan="1" colspan="1">.104</td><td align="center" rowspan="1" colspan="1">0.016</td><td align="center" rowspan="1" colspan="1">.117</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension-LBP</td><td align="center" rowspan="1" colspan="1">.016</td><td align="center" rowspan="1" colspan="1">0.686</td><td align="center" rowspan="1" colspan="1">.021</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-c levels-LBP</td><td align="center" rowspan="1" colspan="1">.618</td><td align="center" rowspan="1" colspan="1">0.784</td><td align="center" rowspan="1" colspan="1">.787</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglyceride levels-LBP</td><td align="center" rowspan="1" colspan="1">.0013</td><td align="center" rowspan="1" colspan="1">0.52</td><td align="center" rowspan="1" colspan="1">.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting blood glucose-LBP</td><td align="center" rowspan="1" colspan="1">.012</td><td align="center" rowspan="1" colspan="1">0.119</td><td align="center" rowspan="1" colspan="1">.285</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin resistance-LBP</td><td align="center" rowspan="1" colspan="1">.005</td><td align="center" rowspan="1" colspan="1">0.817</td><td align="center" rowspan="1" colspan="1">.016</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>HDL-c = high density lipoprotein cholesterol, LBP = lipopolysaccharide-binding protein, LPS = lipopolysaccharide, NAFLD = nonalcoholic fatty liver disease.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2"><label>Figure 2.</label><caption><p>The IVW method to determine whether LPS is a risk factor for MAFLD. IVW = inverse variance weighted, LPS = lipopolysaccharides, MAFLD = metabolic dysfunction-associated fatty liver disease.</p></caption><graphic xlink:href="medi-104-e42311-g002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3.</label><caption><p>The IVW method to determine whether MAFLD is a risk factor for LPS elevation. IVW = inverse variance weighted, LPS = lipopolysaccharides, MAFLD = metabolic dysfunction-associated fatty liver disease.</p></caption><graphic xlink:href="medi-104-e42311-g003" position="float"/></fig></sec><sec><title>3.3. Bidirectional MR of LBP and MAFLD</title><p>LBP was not found to be a risk factor for MAFLD-related diseases. In the reverse MR analysis (NAFLD, liver fat percentage, overweight, obesity, HDL-c, FBG, and IR [analysis significance threshold of <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;6</sup>] as well as T2DM, waist circumference, hypertension, and TG levels [analysis significance threshold of <italic toggle="yes">P</italic>&#x02005;&#x0003c;&#x02005;5&#x02005;&#x000d7;&#x02005;10<sup>&#x02212;8</sup>]), a significant causal relationship was noticed between TG levels and LBP (an increase in TG levels correlated with a decrease in LBP [OR: 0.898, 95% CI: 0.831&#x02013;0.971, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.007]). (Figure S2, Supplemental Digital Content, <ext-link xlink:href="https://links.lww.com/MD/O882" ext-link-type="uri">https://links.lww.com/MD/O882</ext-link> the Scatter plot, funnel plot, forest plot, and leave-one-out sensitivity analysis in MR analysis of LBP and TG) Based on the results of Cochran&#x02019;s Q-test (significant heterogeneity [Q&#x02005;=&#x02005;334.97, <italic toggle="yes">P</italic>&#x02005;=&#x02005;.0013]) and MR-PRESSO global test (<italic toggle="yes">P</italic> value&#x02005;=&#x02005;.002), presence of horizontal pleiotropy was established. However, outlier corrected test showed no outlier SNPs (MR-Egger intercept&#x02005;=&#x02005;0.001, Egger intercept <italic toggle="yes">P</italic> value&#x02005;=&#x02005;.52, no horizontal pleiotropy). Figures <xref rid="F4" ref-type="fig">4</xref> and <xref rid="F5" ref-type="fig">5</xref> show relevant forest maps.</p><fig position="float" id="F4"><label>Figure 4.</label><caption><p>The IVW method to determine whether LBP is a risk factor for MAFLD. IVW = inverse variance weighted, LBPs = LPS-binding proteins, MAFLD = metabolic dysfunction-associated fatty liver disease.</p></caption><graphic xlink:href="medi-104-e42311-g004" position="float"/></fig><fig position="float" id="F5"><label>Figure 5.</label><caption><p>The IVW method to determine whether MAFLD is a risk factor for LBP elevation. IVW = inverse variance weighted, LBPs = LPS-binding proteins, MAFLD = metabolic dysfunction-associated fatty liver disease.</p></caption><graphic xlink:href="medi-104-e42311-g005" position="float"/></fig></sec></sec><sec sec-type="discussion"><title>4. Discussion</title><p>This study identified a causal association among LPS, LBP, NAFLD, and related metabolic disorders; LPS is a risk factor for NAFLD, obesity, HDL-c levels, and TG levels. Furthermore, LBS is a protective factor against elevated TG levels. Based on the best of our knowledge, this is the first study in which MR analysis was formed to determine the association between LPS, LBS, and NAFLD.</p><p>Previously, a meta-analysis of 43 studies showed that blood LPS is a good marker for NAFLD and its staging, and blood LPS levels can also serve as a marker for evaluating intestinal permeability in NAFLD.<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> Heng Yuan et al found that LPS biosynthesis is higher in Asian patients with MAFLD compared with that in patients with no MAFLD.<sup>[<xref rid="R34" ref-type="bibr">34</xref>]</sup> Previous experiments conducted in rats also suggested that LPS can promote the occurrence and development of fatty liver.<sup>[<xref rid="R35" ref-type="bibr">35</xref>]</sup> The journey of LPS to the liver initiates from the gut where dysbiosis of gut microbiota damages the intestinal barrier function, subsequently leading to a leakage of LPS to the bloodstream. LPS utilizes the portal vein and TLR4 receptors to reach the liver and triggers Kupffer cells to produce various inflammatory cytokines and cause liver damage.<sup>[<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref>]</sup> It has been demonstrated that LPS increases the lipid accumulation in liver cells by inhibiting DNA methyltransferase 3B (DNMT3B), thereby reducing CIDEA promoter methylation. The present study clarifies the fact that an initial imbalance in gut microflora and bacterial translocation in bloodstream lead to increase in the rate of NAFLD.<sup>[<xref rid="R38" ref-type="bibr">38</xref>]</sup> Hence, to control MAFLD pathogenesis, the role of gut microbiota should be considered. By implementing methods, such as diet, use of probiotics, and fecal microbiota transplantation, it may be possible to reduce inflammation and IR, improve lipid and glucose metabolism disorders, and thereby reduce MAFLD incidence.<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup></p><p>The present study showed that an increase in LPS levels also raises the incidence of obesity and lipid disequilibrium (decrease in HDL-c levels and increase in TG levels). Consistent with these results, a previous prospective study that conducted a 6-year follow-up of 393 adolescents found that serum LPS predicted obesity, high TG levels and low HDL-c levels.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> Another study conducting a meta-analysis showed a negative correlation between LPS and high HDL-c levels.<sup>[<xref rid="R40" ref-type="bibr">40</xref>]</sup> Several animal studies have also shown similar results; LPS was shown to decrease HDL-c levels and increase TG levels in mice.<sup>[<xref rid="R41" ref-type="bibr">41</xref>&#x02013;<xref rid="R43" ref-type="bibr">43</xref>]</sup> A previous cross-sectional study also demonstrated a close association of LPS with visceral fat in 41 participants with normal BMI; the TG level of the high visceral fat group was significantly higher than that of the low visceral fat group.<sup>[<xref rid="R44" ref-type="bibr">44</xref>]</sup> Inflammation is an important pathogenesis of hyperlipidemia and a driving factor connecting obesity and gut microbiota. Excessive inflammation can lead to metabolic diseases, such as obesity and hyperlipidemia.<sup>[<xref rid="R45" ref-type="bibr">45</xref>]</sup> When the intestinal barrier is damaged, LPS enters the circulation and activates the TLR4-NF-&#x003ba;B-IL-1b/IL-6/TNF-&#x00251; axis to release inflammatory cytokines. Inflammation reduces lipid metabolism in the liver and adipose tissue, leading to obesity, T2DM, and hyperlipidemia. Studies have shown that low-dose LPS can cause lipid metabolism disorders in humans.<sup>[<xref rid="R46" ref-type="bibr">46</xref>&#x02013;<xref rid="R48" ref-type="bibr">48</xref>]</sup> Interestingly, a research has observed that the vitamin D levels in sheep exhibit significant fluctuations between the summer and winter months, yet detect no significant alterations during an immune challenge with LPS endotoxin.<sup>[<xref rid="R49" ref-type="bibr">49</xref>]</sup> A meta-analysis has found that supplementation with vitamin D may lower the incidence of SARS-CoV-2 infections necessitating ICU admission and mechanical ventilation.<sup>[<xref rid="R50" ref-type="bibr">50</xref>]</sup> Given the vital role that vitamin D plays in sustaining peak immune function, it is imperative to conduct additional research into the correlation between fluctuations in vitamin D levels and LPS to better understand how they may influence metabolic disruptions.</p><p>LBPs are acute phase reactive proteins, with a high affinity for the lipid A portion of LPS, and hence these proteins can display proinflammatory and anti-inflammatory actions. The present study showed a causal relationship between TG levels and LBPs (decreased LBP levels are related to increased TG levels). No correlation of LBPs was found with NAFLD, T2DM, obesity, waist circumference, and FBG. Using multifactorial logistic regression analysis, a previous cross-sectional study demonstrated that LBPs are independent protective factors for T2DM and NAFLD. In addition, LBPs were positively correlated with waist circumference and negatively correlated with FBG. Hence, LBPs can promote favorable glucose metabolism to avoid NAFLD.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> Another study suggested that LBPs are biomarkers of obesity-related IR.<sup>[<xref rid="R51" ref-type="bibr">51</xref>]</sup> Although LBP levels were found to be significantly elevated in patients with NAFLD in another study, LBP level was imposed as an independent risk factor for NAFLD. In addition, LBP was significantly positively correlated with TG, FBG, and IR.<sup>[<xref rid="R52" ref-type="bibr">52</xref>]</sup> Furthermore, in a cross-sectional study on the independent correlation between LBP levels and liver fat fraction and liver volume in 99 adolescents with obesity showed that LBP levels can be used as biomarker for predicting high NAFLD risk in adults.<sup>[<xref rid="R53" ref-type="bibr">53</xref>]</sup> Previous epigenetic studies conducted in LBP knockout NAFLD animal models demonstrated decreased inflammation (characterized by decreased levels of IL-6, TNF-&#x00251;), intensified lipid accumulation, and more severe NAFLD. LBP deficiency was mainly attributed to the transcriptional activation of C/EBP-&#x003b2; and SCD, leading to excessive lipid deposition and exacerbating high fat diet (HFD)-induced NAFLD. This also indicates that HFD feeding induced NAFLD models can lead to liver with LBP deficiency.<sup>[<xref rid="R54" ref-type="bibr">54</xref>]</sup> These can, in part, explain the findings of the present study where HFD was found to promote TG levels; hence, increased TG levels or the condition of hypertriglyceridemia, can decrease LBP levels.<sup>[<xref rid="R55" ref-type="bibr">55</xref>]</sup></p><p>In a case-control study involving 386 patients diagnosed with nonalcoholic steatohepatitis (NASH), the analysis revealed that NASH constitutes an independent risk factor for venous thromboembolism (VTE), with a particular association to deep vein thrombosis.<sup>[<xref rid="R56" ref-type="bibr">56</xref>]</sup> This alerts clinicians that such patients frequently necessitate hospitalization and intensive management, encompassing anticoagulation therapy. In recent years, there has also been increasing attention to antiplatelet therapy for NAFLD.<sup>[<xref rid="R57" ref-type="bibr">57</xref>]</sup> Experimental studies have indicated that treatment with aspirin and thienopyridine may alter the progression of liver steatosis, potentially decreasing the incidence of NAFLD and liver fibrosis.<sup>[<xref rid="R58" ref-type="bibr">58</xref>]</sup> Some meta-analyses revealed that both prophylactic anticoagulation and the use of compression stockings were effective in reducing the incidence of venous thromboembolism (VTE).<sup>[<xref rid="R59" ref-type="bibr">59</xref>,<xref rid="R60" ref-type="bibr">60</xref>]</sup></p><p>The main strengths of the present study include high evidence level, effective avoidance of bias, and assessment of reverse causality. Furthermore, the GWAS (database used in the present analysis) had participants with European ethnicities, and hence, we avoided regional and ethnic biases, whereas the exposure and outcome variables came from different study cohort participants, effectively reducing sample overlap. This study also had a few limitations. First, heterogeneity was observed in SNPs between LPS and obesity, without observation of any horizontal pleiotropy. Significant heterogeneity was also detected in SNPs between TG and LBP but with MR-Egger intercept of 0.001. At the same time, the Egger intercept <italic toggle="yes">P</italic> value was .52, indicating no horizontal pleiotropy. Second, this study included only European population. Hence, for other ethnic population, these results will have to be extrapolated. Further studies will be required to verify the findings of this study in other ethnic populations.</p></sec><sec><title>5. Conclusion</title><p>This bidirectional two-sample MR study showed that LPS is a risk factor for NAFLD, obesity, TG, and HDL-C. However, MAFLD did not cause an increase in LPS levels. Targeting the gut microbiota and intestinal barrier may become a highly promising therapy for preventing and treating MAFLD. Although TG levels and LBP levels were found to be negatively correlated, further research is needed to understand the interaction mechanism of LBP and MAFLD.</p></sec><sec><title>Acknowledgments</title><p>We appreciate all the GWAS data provided by <ext-link xlink:href="https://www.ebi.ac.uk/gwa" ext-link-type="uri">https://www.ebi.ac.uk/gwas</ext-link>.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Xixi Han.</p><p><bold>Data curation:</bold> Xixi Han, Chao Wei.</p><p><bold>Formal analysis:</bold> Xixi Han.</p><p><bold>Investigation:</bold> Jingwen Kong, Xixi Han.</p><p><bold>Methodology:</bold> Jingwen Kong, Xixi Han.</p><p><bold>Project administration:</bold> Jingwen Kong, Xixi Han, Chao Wei.</p><p><bold>Resources:</bold> Jingwen Kong, Xixi Han.</p><p><bold>Software:</bold> Jingwen Kong, Xixi Han.</p><p><bold>Supervision:</bold> Xixi Han, Chao Wei.</p><p><bold>Validation:</bold> Chao Wei.</p><p><bold>Writing &#x02013; original draft:</bold> Jingwen Kong.</p><p><bold>Writing &#x02013; review &#x00026; editing:</bold> Jingwen Kong, Chao Wei.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><fig id="s001" position="anchor"><media xlink:href="medi-104-e42311-s001.xlsx"/></fig><fig id="s002" position="anchor"><media xlink:href="medi-104-e42311-s002.pdf"/></fig><fig id="s003" position="anchor"><media xlink:href="medi-104-e42311-s003.pdf"/></fig></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>FBG</term><def><p>fasting blood glucose</p></def></def-item><def-item><term>HDL-c</term><def><p>high density lipoprotein cholesterol</p></def></def-item><def-item><term>LBPs</term><def><p>LPS-binding proteins</p></def></def-item><def-item><term>LPS</term><def><p>lipopolysaccharides</p></def></def-item><def-item><term>MAFLD</term><def><p>metabolic dysfunction-associated fatty liver disease</p></def></def-item><def-item><term>MR</term><def><p>Mendelian randomization</p></def></def-item><def-item><term>NAFLD</term><def><p>nonalcoholic fatty liver disease</p></def></def-item><def-item><term>T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>This paper was supported by the Shandong Provincial Key Laboratory of Traditional Chinese Medicine [no. (2022)4].</p></fn><fn fn-type="other"><p>Ethical approval and consent were not required as this study was based on publicly available data.</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.</p></fn><fn fn-type="supplementary-material"><p>Supplemental Digital Content is available for this article.</p></fn><fn fn-type="other"><p>How to cite this article: Kong J, Han X, Wei C. Causal relationship between metabolic dysfunction-associated fatty liver disease and endotoxin biomarkers: A Mendelian randomization study. Medicine 2025;104:20(e42311).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>VW</given-names></name><name><surname>Ekstedt</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>GL</given-names></name><name><surname>Hagstr&#x000f6;m</surname><given-names>H</given-names></name></person-group>. <article-title>Changing epidemiology, global trends and implications for outcomes of NAFLD.</article-title>
<source>J Hepatol</source>. <year>2023</year>;<volume>79</volume>:<fpage>842</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">37169151</pub-id>
</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younossi</surname><given-names>ZM</given-names></name><name><surname>Golabi</surname><given-names>P</given-names></name><name><surname>Paik</surname><given-names>JM</given-names></name><name><surname>Henry</surname><given-names>A</given-names></name><name><surname>Van Dongen</surname><given-names>C</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name></person-group>. <article-title>The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.</article-title>
<source>Hepatology</source>. <year>2023</year>;<volume>77</volume>:<fpage>1335</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">36626630</pub-id>
</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e9;ndez-S&#x000e1;nchez</surname><given-names>N</given-names></name><name><surname>Bugianesi</surname><given-names>E</given-names></name><name><surname>Gish</surname><given-names>RG</given-names></name><etal/></person-group>; <collab>Global multi-stakeholder consensus on the redefinition of fatty liver disease</collab>. <article-title>Global multi-stakeholder endorsement of the MAFLD definition.</article-title>
<source>Lancet Gastroenterol Hepatol</source>. <year>2022</year>;<volume>7</volume>:<fpage>388</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">35248211</pub-id>
</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>YY</given-names></name><etal/></person-group>. <article-title>MAFLD as part of systemic metabolic dysregulation.</article-title>
<source>Hepatol Int</source>. <year>2024</year>;<volume>18</volume>:<fpage>834</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">38594474</pub-id>
</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eslam</surname><given-names>M</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Francque</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.</article-title>
<source>Nat Rev Gastroenterol Hepatol</source>. <year>2022</year>;<volume>19</volume>:<fpage>638</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">35710982</pub-id>
</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portincasa</surname><given-names>P</given-names></name><name><surname>Baffy</surname><given-names>G</given-names></name></person-group>. <article-title>Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology.</article-title>
<source>Eur J Intern Med</source>. <year>2024</year>;<volume>124</volume>:<fpage>35</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">38653634</pub-id>
</mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>G</given-names></name><name><surname>Faune</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Relation between body composition trajectories from childhood to adolescence and nonalcoholic fatty liver disease risk.</article-title>
<source>Nutrients</source>. <year>2024</year>;<volume>16</volume>:<fpage>785</fpage>.<pub-id pub-id-type="pmid">38542696</pub-id>
</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younossi</surname><given-names>ZM</given-names></name></person-group>. <article-title>Predicting liver-related outcomes in steatotic liver disease.</article-title>
<source>JAMA</source>. <year>2024</year>;<volume>331</volume>:<fpage>1274</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">38512225</pub-id>
</mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellemkj&#x000e6;r</surname><given-names>A</given-names></name><name><surname>Kj&#x000e6;r</surname><given-names>MB</given-names></name><name><surname>Haldrup</surname><given-names>D</given-names></name><name><surname>Gr&#x000f8;nb&#x000e6;k</surname><given-names>H</given-names></name><name><surname>Thomsen</surname><given-names>KL</given-names></name></person-group>. <article-title>Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.</article-title>
<source>Eur J Intern Med</source>. <year>2024</year>;<volume>122</volume>:<fpage>28</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">38008609</pub-id>
</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Sheng</surname><given-names>L</given-names></name></person-group>. <article-title>Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.</article-title>
<source>Life Sci</source>. <year>2023</year>;<volume>321</volume>:<fpage>121614</fpage>.<pub-id pub-id-type="pmid">36965522</pub-id>
</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>YY</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Orally administered octacosanol improves liver insulin resistance in high-fat diet-fed mice through the reconstruction of the gut microbiota structure and inhibition of the TLR4/NF-kappaB inflammatory pathway.</article-title>
<source>Food Funct</source>. <year>2023</year>;<volume>14</volume>:<fpage>769</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">36594412</pub-id>
</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Duan</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>DNMT3B alleviates liver steatosis induced by chronic low-grade LPS via inhibiting CIDEA Expression.</article-title>
<source>Cell Mol Gastroenterol Hepatol</source>. <year>2024</year>;<volume>17</volume>:<fpage>59</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">37703946</pub-id>
</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Dagah</surname><given-names>O</given-names></name><name><surname>Silaa</surname><given-names>BB</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group>. <article-title>Thioredoxin/glutaredoxin systems and gut microbiota in NAFLD: interplay, mechanism, and therapeutical potential.</article-title>
<source>Antioxidants (Basel)</source>. <year>2023</year>;<volume>12</volume>:<fpage>1680</fpage>.<pub-id pub-id-type="pmid">37759983</pub-id>
</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milbank</surname><given-names>E</given-names></name><name><surname>D&#x000ed;az-Trelles</surname><given-names>R</given-names></name><name><surname>Dragano</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Liver lipopolysaccharide binding protein prevents hepatic inflammation in physiological and pathological non-obesogenic conditions.</article-title>
<source>Pharmacol Res</source>. <year>2023</year>;<volume>187</volume>:<fpage>106562</fpage>.<pub-id pub-id-type="pmid">36410673</pub-id>
</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Hakkak</surname><given-names>R</given-names></name></person-group>. <article-title>Feeding soy protein concentrates with low or high isoflavone decreases liver inflammation by reducing lipopolysaccharide translocation.</article-title>
<source>Front Nutr</source>. <year>2023</year>;<volume>10</volume>:<fpage>1278158</fpage>.<pub-id pub-id-type="pmid">38075211</pub-id>
</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perng</surname><given-names>W</given-names></name><name><surname>Friedman</surname><given-names>JE</given-names></name><name><surname>Janssen</surname><given-names>RC</given-names></name><name><surname>Glueck</surname><given-names>DH</given-names></name><name><surname>Dabelea</surname><given-names>D</given-names></name></person-group>. <article-title>Endotoxin biomarkers are associated with adiposity and cardiometabolic risk across 6 years of follow-up in youth.</article-title>
<source>J Clin Endocrinol Metab</source>. <year>2022</year>;<volume>107</volume>:<fpage>e3018</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">35276001</pub-id>
</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barchetta</surname><given-names>I</given-names></name><name><surname>Cimini</surname><given-names>FA</given-names></name><name><surname>Sentinelli</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Reduced Lipopolysaccharide-Binding Protein (LBP) levels are associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and adipose inflammation in human obesity.</article-title>
<source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>:<fpage>17174</fpage>.<pub-id pub-id-type="pmid">38139003</pub-id>
</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>JMG</given-names></name><name><surname>de Assis Costa</surname><given-names>J</given-names></name><name><surname>de Cassia Goncalves alfenas</surname><given-names>R</given-names></name></person-group>. <article-title>Metabolic endotoxemia and diabetes mellitus: a systematic review.</article-title>
<source>Metabolism</source>. <year>2017</year>;<volume>68</volume>:<fpage>133</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">28183445</pub-id>
</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name></person-group>. <article-title>&#x0201c;Mendelian randomization&#x0201d;: can genetic epidemiology contribute to understanding environmental determinants of disease.</article-title>
<source>Int J Epidemiol</source>. <year>2003</year>;<volume>32</volume>:<fpage>1</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">12689998</pub-id>
</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name></person-group>. <article-title>Mendelian randomization: genetic anchors for causal inference in epidemiological studies.</article-title>
<source>Hum Mol Genet</source>. <year>2014</year>;<volume>23</volume>:<fpage>R89</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">25064373</pub-id>
</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghodsian</surname><given-names>N</given-names></name><name><surname>Abner</surname><given-names>E</given-names></name><name><surname>Emdin</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease.</article-title>
<source>Cell Rep Med</source>. <year>2021</year>;<volume>2</volume>:<fpage>100437</fpage>.<pub-id pub-id-type="pmid">34841290</pub-id>
</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Gustafsson</surname><given-names>S</given-names></name><name><surname>M&#x000e4;gi</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture.</article-title>
<source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>:<fpage>501</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">23563607</pub-id>
</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><etal/></person-group>; <collab>eQTLGen Consortium</collab>. <article-title>Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.</article-title>
<source>Nat Commun</source>. <year>2018</year>;<volume>9</volume>:<fpage>2941</fpage>.<pub-id pub-id-type="pmid">30054458</pub-id>
</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prins</surname><given-names>BP</given-names></name><name><surname>Kuchenbaecker</surname><given-names>KB</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Genome-wide analysis of health-related biomarkers in the UK Household Longitudinal Study reveals novel associations.</article-title>
<source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>11008</fpage>.<pub-id pub-id-type="pmid">28887542</pub-id>
</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>AR</given-names></name><name><surname>Sherman</surname><given-names>MA</given-names></name><name><surname>Mukamel</surname><given-names>RE</given-names></name><name><surname>Loh</surname><given-names>PR</given-names></name></person-group>. <article-title>Whole-exome imputation within UK Biobank powers rare coding variant association and fine-mapping analyses.</article-title>
<source>Nat Genet</source>. <year>2021</year>;<volume>53</volume>:<fpage>1260</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">34226706</pub-id>
</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>AK</given-names></name><name><surname>Hivert</surname><given-names>MF</given-names></name><name><surname>Scott</surname><given-names>RA</given-names></name><etal/></person-group>; <collab>DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium</collab>. <article-title>A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.</article-title>
<source>Nat Genet</source>. <year>2012</year>;<volume>44</volume>:<fpage>659</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">22581228</pub-id>
</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupuis</surname><given-names>J</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>Prokopenko</surname><given-names>I</given-names></name><etal/></person-group>; <collab>DIAGRAM Consortium</collab>. <article-title>New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.</article-title>
<source>Nat Genet</source>. <year>2010</year>;<volume>42</volume>:<fpage>105</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">20081858</pub-id>
</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leskel&#x000e4;</surname><given-names>J</given-names></name><name><surname>Toppila</surname><given-names>I</given-names></name><name><surname>H&#x000e4;rma</surname><given-names>MA</given-names></name><etal/></person-group>; <collab>FinnGen</collab>. <article-title>Genetic profile of endotoxemia reveals an association with thromboembolism and stroke.</article-title>
<source>J Am Heart Assoc</source>. <year>2021</year>;<volume>10</volume>:<fpage>e022482</fpage>.<pub-id pub-id-type="pmid">34668383</pub-id>
</mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietzner</surname><given-names>M</given-names></name><name><surname>Wheeler</surname><given-names>E</given-names></name><name><surname>Carrasco-Zanini</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Genetic architecture of host proteins involved in SARS-CoV-2 infection.</article-title>
<source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>:<fpage>6397</fpage>.<pub-id pub-id-type="pmid">33328453</pub-id>
</mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group>. <article-title>Investigation of the association between air pollution and non-alcoholic fatty liver disease in the European population: a mendelian randomization study.</article-title>
<source>Toxics</source>. <year>2024</year>;<volume>12</volume>:<fpage>228</fpage>.<pub-id pub-id-type="pmid">38535961</pub-id>
</mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group>. <article-title>The relationship between major depressive disorder and dementia: a bidirectional two-sample Mendelian randomization study.</article-title>
<source>J Affect Disord</source>. <year>2024</year>;<volume>355</volume>:<fpage>167</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">38548196</pub-id>
</mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>A</given-names></name><name><surname>Xiao</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Causal association of NAFLD with osteoporosis, fracture and falling risk: a bidirectional Mendelian randomization study.</article-title>
<source>Front Endocrinol (Lausanne)</source>. <year>2023</year>;<volume>14</volume>:<fpage>1215790</fpage>.<pub-id pub-id-type="pmid">37621646</pub-id>
</mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soppert</surname><given-names>J</given-names></name><name><surname>Brandt</surname><given-names>EF</given-names></name><name><surname>Heussen</surname><given-names>NM</given-names></name><etal/></person-group>. <article-title>Blood endotoxin levels as biomarker of nonalcoholic fatty liver disease: a systematic review and meta-analysis.</article-title>
<source>Clin Gastroenterol Hepatol</source>. <year>2023</year>;<volume>21</volume>:<fpage>2746</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">36470528</pub-id>
</mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>S</given-names></name></person-group>. <article-title>Microbial dysbiosis linked to metabolic dysfunction-associated fatty liver disease in Asians: prevotella copri promotes lipopolysaccharide biosynthesis and network instability in the prevotella enterotype.</article-title>
<source>Int J Mol Sci</source> . <year>2024</year>;<volume>25</volume>:<fpage>2183</fpage>.<pub-id pub-id-type="pmid">38396863</pub-id>
</mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickerson</surname><given-names>RN</given-names></name><name><surname>Karwoski</surname><given-names>CB</given-names></name></person-group>. <article-title>Endotoxin-mediated hepatic lipid accumulation during parenteral nutrition in rats.</article-title>
<source>J Am Coll Nutr</source>. <year>2002</year>;<volume>21</volume>:<fpage>351</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">12166533</pub-id>
</mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Violi</surname><given-names>F</given-names></name><name><surname>Pastori</surname><given-names>D</given-names></name><name><surname>Pignatelli</surname><given-names>P</given-names></name><name><surname>Cammisotto</surname><given-names>V</given-names></name></person-group>. <article-title>Endotoxemia and platelets: 2 Players of intrahepatic microthrombosis in NAFLD.</article-title>
<source>JACC Basic Transl Sci</source>. <year>2024</year>;<volume>9</volume>:<fpage>404</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">38559621</pub-id>
</mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>V</given-names></name><name><surname>Baumann</surname><given-names>A</given-names></name><name><surname>Brandt</surname><given-names>A</given-names></name><name><surname>Wodak</surname><given-names>MF</given-names></name><name><surname>Staltner</surname><given-names>R</given-names></name><name><surname>Bergheim</surname><given-names>I</given-names></name></person-group>. <article-title>Oral supplementation of phosphatidylcholine attenuates the onset of a diet-induced metabolic dysfunction-associated steatohepatitis in female C57BL/6J Mice.</article-title>
<source>Cell Mol Gastroenterol Hepatol</source>. <year>2024</year>;<volume>17</volume>:<fpage>785</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">38262589</pub-id>
</mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arab</surname><given-names>JP</given-names></name><name><surname>Martin-Mateos</surname><given-names>RM</given-names></name><name><surname>Shah</surname><given-names>VH</given-names></name></person-group>. <article-title>Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.</article-title>
<source>Hepatol Int</source>. <year>2018</year>;<volume>12</volume>:<fpage>24</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">28550391</pub-id>
</mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portincasa</surname><given-names>P</given-names></name><name><surname>Khalil</surname><given-names>M</given-names></name><name><surname>Graziani</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations.</article-title>
<source>Eur J Intern Med</source>. <year>2024</year>;<volume>119</volume>:<fpage>13</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">37802720</pub-id>
</mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e4;&#x000e4;tt&#x000e4;</surname><given-names>AM</given-names></name><name><surname>Salminen</surname><given-names>A</given-names></name><name><surname>Pieti&#x000e4;inen</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Endotoxemia is associated with an adverse metabolic profile.</article-title>
<source>Innate Immun</source>. <year>2021</year>;<volume>27</volume>:<fpage>3</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">33243051</pub-id>
</mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>SY</given-names></name><name><surname>Lordan</surname><given-names>R</given-names></name><name><surname>Meng</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Differential Impact In Vivo of Pf4-&#x00394;Cre-Mediated and Gp1ba-&#x00394;Cre-Mediated Depletion of Cyclooxygenase-1 in Platelets in Mice.</article-title>
<source>Arterioscler Thromb Vasc Biol</source>. <year>2024</year>;<volume>44</volume>:<fpage>1393</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">38660804</pub-id>
</mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>SL</given-names></name><name><surname>Yu</surname><given-names>XH</given-names></name><etal/></person-group>. <article-title>Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE(-/-) mice possibly via activated STAT3-mediated upregulation of tristetraprolin.</article-title>
<source>Acta Pharmacol Sin</source>. <year>2013</year>;<volume>34</volume>:<fpage>837</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">23564081</pub-id>
</mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvi</surname><given-names>SS</given-names></name><name><surname>Ansari</surname><given-names>IA</given-names></name><name><surname>Ahmad</surname><given-names>MK</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>MS</given-names></name></person-group>. <article-title>Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity.</article-title>
<source>Biomed Pharmacother</source>. <year>2017</year>;<volume>96</volume>:<fpage>1082</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">29174038</pub-id>
</mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Gut microbiome alterations in patients with visceral obesity based on quantitative computed tomography.</article-title>
<source>Front Cell Infect Microbiol</source>. <year>2021</year>;<volume>11</volume>:<fpage>823262</fpage>.<pub-id pub-id-type="pmid">35127566</pub-id>
</mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagheri</surname><given-names>S</given-names></name><name><surname>Zolghadri</surname><given-names>S</given-names></name><name><surname>Stanek</surname><given-names>A</given-names></name></person-group>. <article-title>Beneficial effects of anti-inflammatory diet in modulating gut microbiota and controlling obesity.</article-title>
<source>Nutrients</source>. <year>2022</year>;<volume>14</volume>:<fpage>3985</fpage>.<pub-id pub-id-type="pmid">36235638</pub-id>
</mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name></person-group>. <article-title>Impact of gut microbiota and microbiota-related metabolites on hyperlipidemia.</article-title>
<source>Front Cell Infect Microbiol</source>. <year>2021</year>;<volume>11</volume>:<fpage>634780</fpage>.<pub-id pub-id-type="pmid">34490132</pub-id>
</mixed-citation></ref><ref id="R47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Nie</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Oil mistparticulate matter exposure induces hyperlipidemia-related inflammation via microbiota/ SCFAs/GPR43 axis inhibition and TLR4/NF-&#x003ba;B activation.</article-title>
<source>Environ Pollut</source>. <year>2024</year>;<volume>344</volume>:<fpage>123331</fpage>.<pub-id pub-id-type="pmid">38199482</pub-id>
</mixed-citation></ref><ref id="R48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>A</given-names></name><name><surname>Behl</surname><given-names>T</given-names></name><name><surname>Sehgal</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Unravelling the involvement of gut microbiota in type 2 diabetes mellitus.</article-title>
<source>Life Sci</source>. <year>2021</year>;<volume>273</volume>:<fpage>119311</fpage>.<pub-id pub-id-type="pmid">33662428</pub-id>
</mixed-citation></ref><ref id="R49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randle</surname><given-names>S</given-names></name><name><surname>Wagter-Lesperance</surname><given-names>L</given-names></name><name><surname>Dixon</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Variation in ovine serum vitamin D concentrations from late summer to early spring and during immune challenge with bacterial endotoxin.</article-title>
<source>Vet Immunol Immunopathol</source>. <year>2024</year>;<volume>279</volume>:<fpage>110856</fpage>.<pub-id pub-id-type="pmid">39579673</pub-id>
</mixed-citation></ref><ref id="R50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>The role of vitamin D in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials.</article-title>
<source>Clin Nutr</source>. <year>2023</year>;<volume>42</volume>:<fpage>2198</fpage>&#x02013;<lpage>206</lpage>.<pub-id pub-id-type="pmid">37802017</pub-id>
</mixed-citation></ref><ref id="R51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Navarrete</surname><given-names>JM</given-names></name><name><surname>Ortega</surname><given-names>F</given-names></name><name><surname>Serino</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance.</article-title>
<source>Int J Obes (Lond)</source>. <year>2012</year>;<volume>36</volume>:<fpage>1442</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22184060</pub-id>
</mixed-citation></ref><ref id="R52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>VW</given-names></name><name><surname>Wong</surname><given-names>GL</given-names></name><name><surname>Chan</surname><given-names>HY</given-names></name><etal/></person-group>. <article-title>Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study.</article-title>
<source>Aliment Pharmacol Ther</source>. <year>2015</year>;<volume>42</volume>:<fpage>731</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">26202818</pub-id>
</mixed-citation></ref><ref id="R53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perng</surname><given-names>W</given-names></name><name><surname>Salmon</surname><given-names>K</given-names></name><name><surname>Schenker</surname><given-names>R</given-names></name><name><surname>Janssen</surname><given-names>RC</given-names></name><name><surname>Friedman</surname><given-names>JE</given-names></name><name><surname>Goran</surname><given-names>MI</given-names></name></person-group>. <article-title>Endotoxin biomarkers, hepatic fat fraction, liver volume and liver stiffness among adolescents at high-risk for non-alcoholic fatty liver disease: the HEROES study.</article-title>
<source>Pediatr Obes</source>. <year>2024</year>;<volume>19</volume>:<fpage>e13091</fpage>.<pub-id pub-id-type="pmid">38084670</pub-id>
</mixed-citation></ref><ref id="R54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>YL</given-names></name><name><surname>Meng</surname><given-names>LL</given-names></name><name><surname>Ma</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Loss of LBP triggers lipid metabolic disorder through H3K27 acetylation-mediated C/EBP&#x003b2;- SCD activation in non-alcoholic fatty liver disease.</article-title>
<source>Zool Res</source>. <year>2024</year>;<volume>45</volume>:<fpage>79</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">38114435</pub-id>
</mixed-citation></ref><ref id="R55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panyod</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>W-K</given-names></name><name><surname>Hu</surname><given-names>M-Y</given-names></name><etal/></person-group>. <article-title>Healthy diet intervention reverses the progression of NASH through gut microbiota modulation.</article-title>
<source>Microbiol Spectr</source>. <year>2024</year>;<volume>12</volume>:<fpage>e0186823</fpage>.<pub-id pub-id-type="pmid">38018983</pub-id>
</mixed-citation></ref><ref id="R56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suresh</surname><given-names>MG</given-names></name><name><surname>Gogtay</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>Y</given-names></name><name><surname>Yadukumar</surname><given-names>L</given-names></name><name><surname>Mishra</surname><given-names>AK</given-names></name><name><surname>Abraham</surname><given-names>GM</given-names></name></person-group>. <article-title>Case-control analysis of venous thromboembolism risk in non-alcoholic steatohepatitis diagnosed by transient elastography.</article-title>
<source>World J Clin Cases</source>. <year>2023</year>;<volume>11</volume>:<fpage>8126</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">38130793</pub-id>
</mixed-citation></ref><ref id="R57"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalbeni</surname><given-names>A</given-names></name><name><surname>Castelli</surname><given-names>M</given-names></name><name><surname>Zoncap&#x000e8;</surname><given-names>M</given-names></name><name><surname>Minuz</surname><given-names>P</given-names></name><name><surname>Sacerdoti</surname><given-names>D</given-names></name></person-group>. <article-title>Platelets in non-alcoholic fatty liver disease.</article-title>
<source>Front Pharmacol</source>. <year>2022</year>;<volume>13</volume>:<fpage>842636</fpage>.<pub-id pub-id-type="pmid">35250588</pub-id>
</mixed-citation></ref><ref id="R58"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpino</surname><given-names>G</given-names></name><name><surname>Del Ben</surname><given-names>M</given-names></name><name><surname>Pastori</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Increased liver localization of lipopolysaccharides in human and experimental NAFLD.</article-title>
<source>Hepatology</source>. <year>2020</year>;<volume>72</volume>:<fpage>470</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">31808577</pub-id>
</mixed-citation></ref><ref id="R59"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name></person-group>. <article-title>Is it necessary to wear compression stockings and how long should they be worn for preventing post thrombotic syndrome? A meta-analysis of randomized controlled trials.</article-title>
<source>Thromb Res</source>. <year>2023</year>;<volume>225</volume>:<fpage>79</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">37030189</pub-id>
</mixed-citation></ref><ref id="R60"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient, and postdischarge prophylaxis: a meta-analysis of randomized controlled trials.</article-title>
<source>Int J Surg</source>. <year>2024</year>;<volume>110</volume>:<fpage>3910</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">38549227</pub-id>
</mixed-citation></ref></ref-list></back></article>